Loading...

Epigenomics AG

EPGNFPNK
Healthcare
Medical - Diagnostics & Research
$1.12
$0.00(0.00%)

Epigenomics AG (EPGNF) Company Profile & Overview

Explore Epigenomics AG’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Epigenomics AG (EPGNF) Company Profile & Overview

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

SectorHealthcare
IndustryMedical - Diagnostics & Research
CEONoel Thomas Doheny

Contact Information

49 30 243 450
Geneststrasse 5, Heidelberg, 10829

Company Facts

6 Employees
IPO DateDec 31, 2010
CountryDE
Actively Trading

Frequently Asked Questions

;